Press Releases

Press Releases

Samsung Biologics Achieves ISO 27001 Certification, A First in the CDMO Industry

ISO 27001 Certificate Awarding Ceremony

Incheon, S. Korea, 14 November 2019 ? Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security management. Samsung Biologics is the first CDMO company to be ISO 27001 certified globally.

A ceremony was held at Samsung Biologics’ headquarters in Songdo, on Nov 14th, where the German Ambassador to Korea, Stefan Auer, awarded the certificate to Samsung Biologics on behalf of DQS, the ISO 27001 certification body in Germany designated by the International Organization for Standardization.

To be ISO 27001 certified, a company must pass rigorous reviews on 114 items in 14 categories including managerial, physical, technical, and IT security management.

As part of a natural business process, a contract manufacturer receives all relevant product information from its client, and security becomes critical as the transferred data includes a wide range of information from development data to mass production technology, which are highly business sensitive and critical information for the client.

“This achievement is exemplary of our dedication and continuous drive to further enhance the client experience, trust, and satisfaction at Samsung Biologics,” said Andy Kim, VP, in charge of Information Security.

Winning the CMO Leadership Awards for six consecutive years since 2013, Samsung Biologics has proven its expertise and reliability with a continued strength in high-quality product manufacturing and cost-effective services.

With its ability to address clients’ needs all from a single site, Samsung Biologics is a qualified CDMO as repeatedly chosen by clients and is uniquely able to support the development and manufacturing of both large and small scale at every stage of the process while meeting the evolving needs of biopharma/pharma companies worldwide.

ISO 27001 Certificate
iso%20%C1%D6%C7%D1%B5%B6%C0%CF%B4%EB%BB%E7.jpg

Incheon, S. Korea, 14 November 2019 ? Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security management. Samsung Biologics is the first CDMO company to be ISO 27001 certified globally.

A ceremony was held at Samsung Biologics’ headquarters in Songdo, on Nov 14th, where the German Ambassador to Korea, Stefan Auer, awarded the certificate to Samsung Biologics on behalf of DQS, the ISO 27001 certification body in Germany designated by the International Organization for Standardization.

To be ISO 27001 certified, a company must pass rigorous reviews on 114 items in 14 categories including managerial, physical, technical, and IT security management.

As part of a natural business process, a contract manufacturer receives all relevant product information from its client, and security becomes critical as the transferred data includes a wide range of information from development data to mass production technology, which are highly business sensitive and critical information for the client.

“This achievement is exemplary of our dedication and continuous drive to further enhance the client experience, trust, and satisfaction at Samsung Biologics,” said Andy Kim, VP, in charge of Information Security.

Winning the CMO Leadership Awards for six consecutive years since 2013, Samsung Biologics has proven its expertise and reliability with a continued strength in high-quality product manufacturing and cost-effective services.

With its ability to address clients’ needs all from a single site, Samsung Biologics is a qualified CDMO as repeatedly chosen by clients and is uniquely able to support the development and manufacturing of both large and small scale at every stage of the process while meeting the evolving needs of biopharma/pharma companies worldwide.

20191114135521Bd2062e1c-9d9c-4a82-ac81-60c44ac8584c.png

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION